Trade Elicit Therapeutics Inc. - ELTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1168 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.6666 |
| Open | 4.7366 |
| 1-Year Change | -49.27% |
| Day's Range | 4.7366 - 4.7666 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 4.7666 | 0.2600 | 5.77% | 4.5066 | 4.7666 | 4.5066 |
| Jul 24, 2024 | 4.4966 | 0.2200 | 5.14% | 4.2766 | 4.6766 | 4.2766 |
| Jul 23, 2024 | 4.5466 | -0.0300 | -0.66% | 4.5766 | 4.8666 | 4.2766 |
| Jul 22, 2024 | 4.3666 | 0.0800 | 1.87% | 4.2866 | 4.6766 | 4.0466 |
| Jul 19, 2024 | 4.2766 | -0.1400 | -3.17% | 4.4166 | 4.7266 | 4.2666 |
| Jul 18, 2024 | 4.3366 | -0.2800 | -6.07% | 4.6166 | 4.8766 | 4.3066 |
| Jul 17, 2024 | 4.6466 | 0.1600 | 3.57% | 4.4866 | 4.8666 | 4.3466 |
| Jul 16, 2024 | 4.4766 | 0.4500 | 11.18% | 4.0266 | 4.5666 | 4.0266 |
| Jul 15, 2024 | 4.1566 | -0.1600 | -3.71% | 4.3166 | 4.5266 | 4.0266 |
| Jul 12, 2024 | 4.5266 | -0.0500 | -1.09% | 4.5766 | 4.5766 | 4.2966 |
| Jul 11, 2024 | 4.4866 | 0.2500 | 5.90% | 4.2366 | 4.5366 | 4.2066 |
| Jul 10, 2024 | 4.4766 | 0.4500 | 11.18% | 4.0266 | 4.6666 | 3.3266 |
| Jul 9, 2024 | 4.1266 | 0.6300 | 18.02% | 3.4966 | 4.1266 | 3.3366 |
| Jul 8, 2024 | 3.6266 | -0.0200 | -0.55% | 3.6466 | 3.6666 | 3.3766 |
| Jul 5, 2024 | 3.5766 | -0.1900 | -5.04% | 3.7666 | 3.9566 | 3.4766 |
| Jul 3, 2024 | 3.6266 | 0.1500 | 4.31% | 3.4766 | 3.6766 | 3.4766 |
| Jul 2, 2024 | 3.3566 | -0.4200 | -11.12% | 3.7766 | 3.9766 | 3.2766 |
| Jul 1, 2024 | 3.6866 | -0.5300 | -12.57% | 4.2166 | 4.2766 | 3.4766 |
| Jun 28, 2024 | 4.0766 | 0.0500 | 1.24% | 4.0266 | 4.7166 | 4.0266 |
| Jun 27, 2024 | 6.7866 | 0.3900 | 6.10% | 6.3966 | 6.7866 | 6.3966 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Angion Biomedica Corp. Company profile
About Angion Biomedica Corp
Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The Company’s other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Angion Biomedica Corp revenues decreased 2% to $2.4M. Net loss increased 36% to $69.5M. Revenues reflect Grant revenue decrease from $2.4M to $0K. Higher net loss reflects Research and development - Balancing increase of 40% to $36.9M (expense), Other Non Operati decrease from $10K (income) to $3.6M (expense), Stock-based Compensation in R&D increase from $1.6M to $5.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
451 D Street, 5Th Floor
BOSTON
MASSACHUSETTS 02459
US
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com